Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla’s Long Road To Riquent Approval Takes Another Turn

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

La Jolla Pharmaceutical is modifying an ongoing Phase III trial evaluating its systemic lupus erythematosus candidate Riquent (abetimus) in a manner that will push back the study findings beyond the latest anticipated timeline

You may also be interested in...



Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE

Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.

Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE

Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.

La Jolla reactivates Phase III Riquent trial

La Jolla has reactivated enrollment in a Phase III trial of Riquent (abetimus sodium) in lupus renal disease under a special protocol assessment. The trial is being conducted at FDA's request based on clinical deficiencies relating to the firm's previous Phase II and Phase III trials cited in an October 2004 "approvable" letter (1Pharmaceutical Approvals Monthly November 2004, p. 13). FDA recommended another study to distinguish Riquent from placebo through an endpoint such as time to renal flare. La Jolla plans to enroll 600 patients by the second half of 2007 and has expanded the trial to include Europe and Mexico...

Topics

UsernamePublicRestriction

Register

PS003835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel